AI-based sarcopenia prediction solution company Biobytes successfully closed a 600 million KRW Seed round. This round was led by UK-based venture capital Kingsley Ventures, with Sopung Ventures, CNT Tech, and Gangwon Creative Economy Innovation Center also participating. Biobytes stated it will use the investment raised in this round to accelerate multi-institutional biobank data collection and hire new specialized personnel. Biobytes is a bio-healthcare company focused on sarcopenia diagnosis and treatment. Sarcopenia (age-related muscle loss) is a growing healthcare challenge as global populations age -- affecting 10-16% of people over 60 and significantly increasing fall, fracture, and mortality risk; current diagnosis requires DXA scans or muscle biopsy which are expensive and not widely accessible; Biobytes AI-based prediction model uses more accessible data inputs (gait analysis, grip strength, biomarkers) to predict sarcopenia risk before it reaches clinical threshold; the multi-institutional biobank data collection will enable the model to be trained on diverse patient populations, improving generalizability across ethnicities and body types; the 600 million KRW Seed round positions Biobytes for clinical validation studies and regulatory approval pathways in Korea and potentially Japan, where aging population demographics create strong market demand.